REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr....

12
REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR : Dr. D.RAMAMURTHY CO – AUTHOR : Dr. R.CHITRA The authors have no financial interest in the subject matter of this poster THE EYE FOUNDATION COIMBATORE & TIRUPUR INDIA

Transcript of REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr....

Page 1: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject.

REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS

CHIEF AUTHOR : Dr. D.RAMAMURTHYCO – AUTHOR : Dr. R.CHITRA

The authors have no financial interest in the subject matter of this poster

THE EYE FOUNDATIONCOIMBATORE & TIRUPURINDIA

Page 2: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject.

TORIC ICL – REFRACTIVE OUTCOMES

PURPOSE

TO STUDY THE EFFICACY AND PREDICTABILITY

OF THE FIRST 100 CONSECUTIVE

TORIC ICL IMPLANTS

Page 3: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject.

TORIC ICL – REFRACTIVE OUTCOMES

MATERIALS & METHODS

NUMBER OF PATIENTS - 69

(MALE – 40, FEMALE - 29)

NUMBER OF EYES - 100 (UNILATERAL – 38, BILATERAL- 31)

AGE GROUP - 18 TO 48

PERIOD OF FOLLOW-UP - 2 TO 24 MONTHS

STUDY PERIOD - MAY 2007 TO DEC 2009

Page 4: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject.

TORIC ICL – REFRACTIVE OUTCOMES

INCLUSION CRITERIA

AGE ABOVE 18 YEARS WITH STABLE REFRACTION FOR ATLEAST ONE YEAR

NOT IN THE RANGE FOR LASER VISION CORRECTION CORNEAL THICKNESS < 480 µ RESIDUAL BED < 300 µ ASTIGMATISM > 3 D SPHERICAL EQUIVALENT > 12 D ANY EVIDENCE OF FORME FRUSTE KERATOCONUS

AC DEPTH > 2.8 mm

OTHERWISE NORMAL EYES (MILD TO MODERATE MYOPIC MACULAR DEGENARATION NOT CONSIDERED AS AN EXCLUSION)

Page 5: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject.

TORIC ICL – REFRACTIVE OUTCOMES

PROCEDURE

SIZING BASED ON CALIPERS & ORBSCAN W to W MEASUREMENT

YAG IRIDOTOMY 1 WEEK BEFORE SURGERY

TOPICAL ANAESTHESIA

AXIS MARKING WITH PATIENT SITTING IN OPERATION THEATRE

TEMPORAL 3.2 mm INCISION

Page 6: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject.

TORIC ICL – REFRACTIVE OUTCOMES

VISUAL OUTCOMES

VISUAL ACUITY

PRE-OP

BCVA

(No of Eyes)

POST OP UCVA AT

FINAL FOLLOW UP

(No of Eyes)

POST OP BCVA AT FINAL

FOLLOW UP

(No of Eyes)

6/6 36 36 38

6/9 48 45 43

6/12 5 12 8

6/18 7 5 7

< 6/60 4 2 4

05

101520253035404550

6/6 6/9 6/12 6/18 <6/60

PRE-OP BCVA

POST-OPUCVA @ FINALFOLLOW UP

POST-OPBCVA @ FINALFOLLOW UP

No

of

EY

ES

VISUAL ACUITY

Page 7: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject.

TORIC ICL – REFRACTIVE OUTCOMES

POWER RANGE CORRECTED

SPHERICAL RANGE - 1.50 TO – 19.00

CYLINDER RANGE - 1.25 TO – 5.5

SPHERICAL EQUIVALENT RANGE 2.75 TO 20

Page 8: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject.

TORIC ICL – REFRACTIVE OUTCOMES

.

RESIDUAL POWER IN SPH EQUIVALENT

BETWEEN 0.25 & 0.5 21 EYES

BETWEEN 0.5 & 1 3 EYES

> 1 1 EYE

Page 9: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject.

TORIC ICL – REFRACTIVE OUTCOMES

RESIDUAL CYLINDER

BETWEEN - 0.25 & - 0.5 2 EYES

BETWEEN - 0.5 & - 1.0 9 EYES

> - 1 5 EYES

Page 10: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject.

TORIC ICL – REFRACTIVE OUTCOMES

RESULTS

VISUAL ACUITY COMPARISON

IMPROVED

(1 LINE)

DIMINISHED

(1 LINE)

IMPROVED OR DIMISHED BY >

1 LINE

CHANGE

<

1 LINE

PRE OP BCVA Vs POST OP UCVA

5 EYES 12 EYES 0 83 EYES

PRE OP BCVA Vs POST OP BCVA

10 EYES 2 EYES 0 88 EYES

Page 11: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject.

TORIC ICL – REFRACTIVE OUTCOMES

COMPLICATIONS PIGMENT DEPOSITS ON ICL & ENDOTHELIUM : 31

EYES

POST OP RAISED IOP CONTROLLED WITH MEDICATION : 7 EYES

LOW VAULT : 8 EYES

EXCESSIVE VAULT: 4 EYES

REPEAT IRIDOTOMY IN POST OP PERIOD : 2 EYES

LOCALIZED ANTERIOR SUBCAPSULAR OPACITY : 1 EYE

ICL REPOSITIONING FOR INAPPROPRIATE AXIS : 2 EYES

HIGH VAULT

Page 12: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject.

TORIC ICL – REFRACTIVE OUTCOMES

CONCLUSION

TORIC ICL SEEMS TO BE A RELIABLE, PREDICTABLE MODALITY

FOR CORRECTING MYOPIC ASTIGMATISM WHICH ARE NOT AMENABLE TO LASER VISION CORRECTION